Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

Table 3 Medical cost according to health status (USD/year/person)

Patient groups	Health status	Annual direct medical cost (USD)
All patients	DM with HF	4964.0
	HF death	6718.1
	DM without HF	813.6
	Other death^a	2919.5
Patients with underlying CVD	DM with HF	5321.5
	HF death	6615.5
	DM without HF	1286.5
	Other death^a	2783.9
Patients without underlying CVD	DM with HF	4701.1
	HF death	6864.5
	DM without HF	743.2
	Other death^a	2964.6

ISSN: 1475-2840